New York, June 5, 2026, 17:02 EDT
- Nutex Health was last quoted at $132.59, down 1.5%, after trading between $130.64 and $136.93.
- The move came as U.S. stocks sold off after May payrolls beat forecasts and pushed Treasury yields higher.
- Investors are weighing Nutex’s cash generation, share buyback and out-of-network billing risks.
Nutex Health Inc. shares fell 1.5% late Friday, leaving the hospital operator at $132.59 after a choppy session that saw the stock swing from $130.64 to $136.93. Volume was 131,507 shares, and the company’s market value stood near $912 million.
The move mattered because it came on a rough tape, not on a clear company-specific headline. The Labor Department said U.S. employers added 172,000 jobs in May and unemployment held at 4.3%, stronger than economists had expected and enough to jolt rate expectations.
That hit risk appetite. The S&P 500 lost 2.6%, the Nasdaq fell 4.2% and the Russell 2000 index of smaller companies dropped 3.5%, according to AP’s market wrap. For a sub-$1 billion healthcare name such as Nutex, that kind of small-cap selloff can matter even when the day’s main pressure starts in macro data.
Nutex’s own story is still tied to whether it can keep turning its hospital network and insurer-payment disputes into cash. The Houston-based company says it runs a Hospital Division and a Population Health Management Division; its hospital business includes micro-hospitals, specialty hospitals and hospital outpatient departments, with 27 facilities in 13 states.
The latest earnings backdrop was mixed but profitable. Nutex said first-quarter revenue rose 2.2% to $216.5 million, net income attributable to the company rose to $46.8 million, and hospital visits increased 3.1%. Adjusted EBITDA, a non-GAAP profit measure that strips out interest, taxes, depreciation, amortization and other company adjustments, fell to $57.6 million from $72.8 million a year earlier.
“Our balance sheet remains very strong,” Chief Financial Officer Jon Bates said in the April results release, citing $207.3 million in cash and planned growth from three hospital openings later this year. Chief Executive Tom Vo said Nutex was making “targeted investments” to drive patient volumes and inpatient admissions. PR Newswire
Peers gave a cleaner read on the sector. Larger hospital operators HCA Healthcare, Tenet Healthcare and Universal Health Services rose 2.9%, 0.4% and 1.7%, respectively, while the Health Care Select Sector SPDR ETF gained 0.6%. Nutex’s decline looked closer to the pressure on smaller stocks than to a broad hospital-sector selloff.
The company’s reimbursement model remains central. Nutex uses Independent Dispute Resolution, or IDR, an arbitration process for settling out-of-network payment fights between providers and insurers under the No Surprises Act. In its quarterly filing, Nutex said the process can take three to five months to receive payments and listed accrued arbitration expenses of $56.8 million as of March 31.
The board has also leaned on buybacks. Nutex said it completed a prior $25 million repurchase program and, as of March 31, had about $23 million remaining under a second $25 million authorization. The program does not force the company to buy shares and may be changed, suspended or ended.
Macro did not help the case for rate-sensitive shares. Jason Pride, chief of investment strategy and research at Glenmede, told Reuters the Fed’s “binding constraint” remained inflation rather than employment after the jobs data. Gary Schlossberg, a market strategist at Wells Fargo Investment Institute, called higher-rate pressure “a headwind” for both the economy and the stock market. Reuters
But the downside case is not just rates. Nutex disclosed pending securities and derivative litigation tied partly to statements about IDR-related claims and stock-based compensation accounting; it said an adverse ruling in the securities case could have a material adverse effect. The company also warned that potential future share issuance obligations tied to former doctor owners of under-construction hospitals could dilute existing holders.
That leaves the stock with two tests. First, whether cash collections and hospital volumes keep offsetting arbitration costs. Second, whether investors stay willing to own a small healthcare operator on days when bond yields rise and smaller stocks are sold first.
